. The company's results were underpinned by solid performance in its proprietary product portfolio. Lybalvi growth continues to accelerate and accounted for 18% of revenues in the second quarter, up from 12% in full year 2023. Although we project revenues to decline to about 6%-8% in 2024, we expect the company's revenues to increase between 5% and 7% when excluding the one-time $197 million back pay for Invega royalties received in 2023. We anticipate revenues to increase by between 4% and 6% in 2025 as the growth in Lybalvi and its other proprietary products are offset by a decline in Invega royalties, a portion of which will end in mid-August of this year. . We forecast the company to generate
